Januray 8 th, 2010
- Aridis out-licenses formulation stabilization technologies to a major vaccine and biologics company. More
September 30th, 2009
- Aridis awarded National Institute of Health grant award to develop new generation of anthrax vaccine. More..
July 17th, 2009
- Aridis awarded SBIR Award from the National Institute of Allergy and Infectious Diseases, NIH to develop inhalable gallium based therapeutics. More..
January 9th, 2009
- Aridis awarded U.S. Agency for International Development (USAID) award in collaboration with Mapp BioPharmaceutical to develop microbicides monoclonal antibodies. More..
September 26th, 2008
- Aridis awarded two technology development grants to develop stabilization technologies for F. tulerensis and filovirus vaccines. More...
February 19th, 2008
- Aridis completed an agreement with the University of Iowa Research Foundation for exclusive worldwide rights to gallium based anti-infective therapeutic drug technology platform (PanaecinTM).
July 15th, 2007
- The National Institutes of Health awarded Aridis and Harvard University with an NIH STTR grant for preclinical development of human monoclonal antibody (AerucinTM) for the treatment of Pseudomonas aeruginosa infetions. More...
June 1st, 2007
- Aridis entered into a formulation development agreement with a nonprofit organization PATH to collaborate on the development of select rotavirus vaccine formulations. This agreement is for a three year period and Aridis will be reimbursed for expenses incurred up to a total of about $1.9 M. More...
July 10th, 2007
- Enwave Corporation and Aridis are working to establish the feasibility of formulating room temperature stable vaccines and antibodies using the EnWave’s bioREV microwave assisted vacuum drying technology. Aridis is reimbursed for expenses. More...
May 15th, 2007
- Aridis' collaboration with Johns Hopkins University on oral thin film delivery systems for vaccines featured in Newsweek and Fox News.